Schuler Megan S, Griffin Beth Ann, Cerdá Magdalena, McGinty Emma E, Stuart Elizabeth A
RAND Corporation, 20 Park Plaza #920, Boston MA USA 02216.
RAND Corporation, 1200 S Hayes Street, Arlington VA USA 22202.
Health Serv Outcomes Res Methodol. 2021 Mar;21(1):21-41. doi: 10.1007/s10742-020-00228-2. Epub 2020 Nov 12.
Opioid-related mortality increased by nearly 400% between 2000 and 2018. In response, federal, state, and local governments have enacted a heterogeneous collection of opioid-related policies in an effort to reverse the opioid crisis, producing a policy landscape that is both complex and dynamic. Correspondingly, there has been a rise in opioid-policy related evaluation studies, as policymakers and other stakeholders seek to understand which policies are most effective. In this paper, we provide an overview of methodological challenges facing opioid policy researchers when evaluating the effects of opioid policies using observational data, as well as some potential solutions to those challenges. In particular, we discuss the following key challenges: (1) Obtaining high-quality opioid policy data; (2) Appropriately operationalizing and specifying opioid policies; (3) Obtaining high-quality opioid outcome data; (4) Addressing confounding due to systematic differences between policy and non-policy states; (5) Identifying heterogeneous policy effects across states, population subgroups, and time; (6) Disentangling effects of concurrent policies; and (7) Overcoming limited statistical power to detect policy effects afforded by commonly-used methods. We discuss each of these challenges and propose some ways forward to address them. Increasing the methodological rigor of opioid evaluation studies is imperative to identifying and implementing opioid policies that are most effective at reducing opioid-related harms.
2000年至2018年间,与阿片类药物相关的死亡率增长了近400%。作为回应,联邦、州和地方政府制定了一系列五花八门的阿片类药物相关政策,试图扭转阿片类药物危机,形成了一个既复杂又动态的政策局面。相应地,随着政策制定者和其他利益相关者试图了解哪些政策最有效,与阿片类药物政策相关的评估研究也有所增加。在本文中,我们概述了阿片类药物政策研究人员在使用观察性数据评估阿片类药物政策效果时面临的方法学挑战,以及应对这些挑战的一些潜在解决方案。具体而言,我们讨论以下关键挑战:(1)获取高质量的阿片类药物政策数据;(2)恰当地实施和明确阿片类药物政策;(3)获取高质量的阿片类药物结果数据;(4)解决因政策实施州和非政策实施州之间的系统差异导致的混杂问题;(5)识别各州、人群亚组和不同时间的异质性政策效果;(6)厘清并行政策的效果;(7)克服常用方法在检测政策效果方面统计效力有限的问题。我们讨论了每一项挑战,并提出了一些应对方法。提高阿片类药物评估研究的方法严谨性对于识别和实施最有效地减少阿片类药物相关危害的政策至关重要。